Clinical trials show that CD47/SIRP⍺ targeting improves outcomes in non-Hodgkin lymphoma, suggesting new therapy avenues.
Multiple CD47/SIRP⍺-targeting therapeutics and multiple clinical trials have demonstrated encouraging results in patients with non-Hodgkin lymphoma, where objective responses have been observed in combination with rituximab and other anti-cancer agents. Next-generation approaches, such as bispecific antibodies and engineering efforts to reduce blood cell binding, are now under clinical development and may be successful strategies to unlock the extraordinary potential of the CD47/SIRP⍺ immune checkpoint.
No takes yet. Share an insight, caveat, or question.
Pagès-Geli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: